Relmada Therapeutics (RLMD) Gross Margin (2012 - 2013)
Relmada Therapeutics (RLMD) reported Gross Margin of 8.86% for Q4 2013, down 505.0% year-over-year from 2.19% in Q4 2012, and down 81.99% quarter-over-quarter from 49.21% in Q2 2013.
Relmada Therapeutics (RLMD) Gross Margin (2012 - 2013) Analysis & Trends
Relmada Therapeutics (RLMD) has 2 years of Gross Margin data on file, last reported at 8.86% in Q4 2013.
- Gross Margin for Q4 2013 came in at 8.86%, down 505.0% year-over-year; the trailing twelve-month figure through Nov 2013 was 19.83% (changed N/A YoY), and the FY2013 annual result was 21.31%, down 566.0% from the prior year.
- Gross Margin declined to 8.86% in Q4 2013 per RLMD's latest filing, from 49.21% in the prior quarter.
- Over five years, Gross Margin peaked at 49.21% in Q2 2013 and troughed at 8.86% in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 79.04% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Relmada Therapeutics | 581.07 Mn | 581.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2013 | 8.86% |
| May 31, 2013 | 49.21% |
| Feb 28, 2013 | 20.55% |
| Nov 30, 2012 | 13.91% |
| Aug 31, 2012 | 34.13% |
| May 31, 2012 | 27.00% |